Pielenhofer, J.; Meiser, S.L.; Gogoll, K.; Ciciliani, A.-M.; Denny, M.; Klak, M.; Lang, B.M.; Staubach, P.; Grabbe, S.; Schild, H.;
et al. Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product. Pharmaceutics 2023, 15, 514.
https://doi.org/10.3390/pharmaceutics15020514
AMA Style
Pielenhofer J, Meiser SL, Gogoll K, Ciciliani A-M, Denny M, Klak M, Lang BM, Staubach P, Grabbe S, Schild H,
et al. Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product. Pharmaceutics. 2023; 15(2):514.
https://doi.org/10.3390/pharmaceutics15020514
Chicago/Turabian Style
Pielenhofer, Jonas, Sophie Luise Meiser, Karsten Gogoll, Anna-Maria Ciciliani, Mark Denny, Michael Klak, Berenice M. Lang, Petra Staubach, Stephan Grabbe, Hansjörg Schild,
and et al. 2023. "Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product" Pharmaceutics 15, no. 2: 514.
https://doi.org/10.3390/pharmaceutics15020514
APA Style
Pielenhofer, J., Meiser, S. L., Gogoll, K., Ciciliani, A. -M., Denny, M., Klak, M., Lang, B. M., Staubach, P., Grabbe, S., Schild, H., Radsak, M. P., Spahn-Langguth, H., & Langguth, P.
(2023). Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product. Pharmaceutics, 15(2), 514.
https://doi.org/10.3390/pharmaceutics15020514